Denton Sheila A.
Known title: SVP, Gen. Counsel & Corp. Sec.CIK: 0001995298
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.
Transaction History
| MMED | ▲ Buy | Grant | 58,939 | $0 | 10/1/2026 | View on chart |
| INCY | ▲ Buy | Option Exercise | 278 | $18K | 11/17/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 278 | $29K | 11/17/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 598 | $35K | 11/4/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 598 | $61K | 11/4/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 277 | $18K | 10/15/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 277 | $24K | 10/15/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 3,501 | $299K | 10/3/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 599 | $35K | 10/2/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 599 | $53K | 10/2/2025 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 3,130 | $270K | 10/2/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 278 | $18K | 9/16/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 278 | $23K | 9/16/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 598 | $35K | 9/2/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 598 | $51K | 9/2/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 277 | $18K | 8/15/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 277 | $24K | 8/15/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 598 | $35K | 8/4/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 598 | $45K | 8/4/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 785 | $54K | 7/16/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 3,330 | $214K | 7/15/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 3,330 | $233K | 7/15/2025 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 703 | $48K | 7/15/2025 | View on chart |
| INCY | ▲ Buy | Grant | 8,184 | $0 | 7/15/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 599 | $35K | 7/2/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 599 | $41K | 7/2/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 1,795 | $104K | 6/3/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 1,795 | $122K | 6/3/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 599 | $35K | 3/4/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 599 | $42K | 3/4/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 9,574 | $556K | 2/26/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 9,574 | $709K | 2/26/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 4,495 | $333K | 2/26/2025 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 2,136 | $144K | 10/2/2024 | View on chart |
| INCY | ▲ Buy | Grant | 5,955 | $0 | 7/15/2024 | View on chart |
| INCY | ▲ Buy | Grant | 26,524 | $0 | 10/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
MiniMed Set for Medtronic Split-Off, Analysts Set New Targets
Medtronic has finalized the exchange ratio for the MiniMed split-off, a key corporate event for the stock. Meanwhile, Mizuho raised its price target to $28, while Barclays initiated coverage with a lower target of $22. Recent studies also highlighted that responding to MiniMed's diabetes alerts is linked to better glucose outcomes.
MiniMed Set for Medtronic Split-Off, Analysts Set New Targets. Medtronic has finalized the exchange ratio for the MiniMed split-off, a key corporate event for the stock. Meanwhile, Mizuho raised its price target to $28, while Barclays initiated coverage with a lower target of $22. Recent studies also highlighted that responding to MiniMed's diabetes alerts is linked to better glucose outcomes.